Transitioning from clozapine to Cobenfy (xanomeline-trospium chloride) in treatment resistant schizophrenia and clozapine induced OCD
Abstract Background Treatment-resistant schizophrenia (TRS) is defined as nonresponse to at least two adequate antipsychotic trials at therapeutic doses for six or more weeks. Currently, clozapine is the only antipsychotic approved for TRS by the FDA and a plethora of evidence indicates that it is t...
محفوظ في:
| المؤلفون الرئيسيون: | , , |
|---|---|
| التنسيق: | Artigo |
| اللغة: | Inglês |
| منشور في: |
BMC
2026-05-01
|
| سلاسل: | BMC Psychiatry |
| الموضوعات: | |
| الوصول للمادة أونلاين: | https://doi.org/10.1186/s12888-026-07795-7 |
| الوسوم: |
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|